[Statlist] FW: Statistics in Biopharmaceutical Research: Special Issue on Covid-19 Clinical Trials

[Blatna, Bibiana]

Dear Colleagues,
We invite submissions to the the special issue of Statistics in Biopharmaceutical Research (SBR)<https://urldefense.proofpoint.com/v2/url?u=https-3A__www.tandfonline.com_toc_usbr20_current&d=DwMDaQ&c=ZbgFmJjg4pdtrnL2HUJUDw&r=RaqW_n1AWPv27bQfBJPNA41zHljmqaq5r6Ean053HW8&m=w6Ewq3x5-nWqssxeSbURHaWPXO2wcOaFTcUoOWQIGi0&s=bNrknC5-af0Sh0HOs7CfzsW5-AFPHu8MlLCkIPlh2hs&e=>: Statistical Issues and Challenges in Clinical Trials for COVID-19 Treatments, Vaccines, Medical devices and Diagnostics.
The deadline for submissions has been extended to 15 November 2020. This is a firm deadline and there will be no further extension. See below for further details.



Call for Papers
Special issue
Statistical Issues and Challenges in Clinical Trials for
COVID-19 Treatments, Vaccines, Medical devices and Diagnostics
The entire globe has been facing a pandemic due to the coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Our biopharmaceutical community has committed to developing solutions to help diagnose and treat those with COVID-19, conducted clinical trials to evaluate effective strategies that can lead to developing diagnostic test to detect SARS-CoV-2 precisely and efficiently, identifying treatments for critical care management of patients, and discovering the highly anticipated vaccines.
Statistics in Biopharmaceutical Research (SBR)<https://urldefense.proofpoint.com/v2/url?u=https-3A__www.tandfonline.com_toc_usbr20_current&d=DwMDaQ&c=ZbgFmJjg4pdtrnL2HUJUDw&r=RaqW_n1AWPv27bQfBJPNA41zHljmqaq5r6Ean053HW8&m=w6Ewq3x5-nWqssxeSbURHaWPXO2wcOaFTcUoOWQIGi0&s=bNrknC5-af0Sh0HOs7CfzsW5-AFPHu8MlLCkIPlh2hs&e=>, an Official Journal of the American Statistical Association (ASA), has been publishing papers on clinical trial disruptions and statistical issues due to COVID-19 pandemic. Now SBR is calling for papers on: Clinical Trials for COVID-19 Treatments, Vaccines, Medical Devices and Diagnostics, which are needed to fight this virus. SBR will accept manuscripts in the form of original research, short communication, perspective, commentary or letter to the editor which can provide a platform for the presentation of recent statistical issues, challenges or methodology developments in our knowledge on COVID-19.
Manuscripts should be submitted online at ScholarOne Manuscripts System https://mc.manuscriptcentral.com/statsbr<https://urldefense.proofpoint.com/v2/url?u=https-3A__mc.manuscriptcentral.com_statsbr&d=DwMDaQ&c=ZbgFmJjg4pdtrnL2HUJUDw&r=RaqW_n1AWPv27bQfBJPNA41zHljmqaq5r6Ean053HW8&m=w6Ewq3x5-nWqssxeSbURHaWPXO2wcOaFTcUoOWQIGi0&s=3oIt95xkOsmEKGmlqLPC1GnwE1H9htBmjOFzpOn4gTk&e=>. Once you login to the system, go to “Start New Submission” page. Please select “COVID-19 Trials” at “Step 1: Type, Title, & Abstract”. Manuscripts can be submitted until the deadline, November 15, 2020. All papers will be peer-reviewed, according to the reviewing principles of SBR. Accepted papers will be published continuously online on the journal website (as soon as accepted) and will be listed together on the special issue.
A guide for authors and other relevant information for submission of manuscripts is available on the “Instructions for Authors” page at the journal website https://www.tandfonline.com/toc/usbr20/current<https://urldefense.proofpoint.com/v2/url?u=https-3A__www.tandfonline.com_toc_usbr20_current&d=DwMDaQ&c=ZbgFmJjg4pdtrnL2HUJUDw&r=RaqW_n1AWPv27bQfBJPNA41zHljmqaq5r6Ean053HW8&m=w6Ewq3x5-nWqssxeSbURHaWPXO2wcOaFTcUoOWQIGi0&s=bNrknC5-af0Sh0HOs7CfzsW5-AFPHu8MlLCkIPlh2hs&e=> and “ASA Style Guide” page at ASA-Taylor and Francis website https://amstat.tfjournals.com/asa-style-guide/<https://urldefense.proofpoint.com/v2/url?u=https-3A__amstat.tfjournals.com_asa-2Dstyle-2Dguide_&d=DwMDaQ&c=ZbgFmJjg4pdtrnL2HUJUDw&r=RaqW_n1AWPv27bQfBJPNA41zHljmqaq5r6Ean053HW8&m=w6Ewq3x5-nWqssxeSbURHaWPXO2wcOaFTcUoOWQIGi0&s=rwgWb3-gozT-Eepu62wemGrjglRehZE1HHsP_VxmSAo&e=>.
If you have any questions or require clarification, please, do not hesitate to reach out to Toshimitsu Hamasaki at thamasaki using gwu.edu<mailto:thamasaki using gwu.edu>, or Freda Cooner (Co-Guest Editor for COVID-19 Special Issue) at fcooner using amgen.com<mailto:fcooner using amgen.com>.
Best regards,
Frank Bretz
on behalf of the COVID-19 Trials Special Editorial Team
Frank Bretz, Novartis; Freda Cooner (Co-Guest Editor), Amgen; Toshimitsu Hamasaki (Co-Guest Editor), The George Washington University; Gene Pennello, US Food and Drug Administration; Martin Posch, Medical University of Vienna

	[[alternative HTML version deleted]]